Health Canada InfoWatch

Health Product InfoWatch: March 2026

Health Canada's March 2026 Health Product InfoWatch details recalls and safety updates for various medications, including Bicillin L-A, Bortezomib, Cefazolin, MAR-Amlodipine, and Seasonique/Seasonale. It also announces new market authorizations with conditions for Voxzogo and product monograph updates for Stivarga.

Health Canada Health Product Safety Recap

Health Canada has issued its February 2026 Health Product InfoWatch, detailing recalls for Teva Octreotide due to GMP deficiencies and unauthorized health products. It also announces a consultation on controlling zuranolone under the Controlled Drugs and Substances Act.

Health Canada Health Product InfoWatch - February 2026

Health Canada's February 2026 Health Product InfoWatch includes a monthly recap of safety information, including a recall of Teva Octreotide and advisories on unauthorized products. It also announces a consultation on controlling zuranolone and new market authorizations with conditions.

Teva Octreotide Recalled Due to Manufacturing Deficiencies

Health Canada has issued a Type I drug recall for Teva Octreotide due to manufacturing site deficiencies identified at a foreign facility. These deficiencies could lead to potential quality issues, including compromised sterility and dosing accuracy. The recall is a precautionary measure.